company background image
HARP

Harpoon TherapeuticsNasdaqGS:HARP Stock Report

Market Cap

US$186.3m

7D

-10.1%

1Y

-52.7%

Updated

02 Dec, 2021

Data

Company Financials +
HARP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

HARP Stock Overview

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Harpoon Therapeutics
Historical stock prices
Current Share PriceUS$6.34
52 Week HighUS$25.24
52 Week LowUS$5.53
Beta0.72
1 Month Change-3.94%
3 Month Change-29.16%
1 Year Change-52.65%
3 Year Changen/a
5 Year Changen/a
Change since IPO-53.04%

Recent News & Updates

Nov 30
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Sep 16

Harpoon Therapeutics: A First Look

Harpoon Therapeutics, Inc. stock is down over 55% since it released data on its most advanced early-stage program (HPN424 for metastatic castration-resistant prostrate cancer) in June 2020. The company has a total of four early-stage programs, the most important of which is HPN217, into which AbbVie can opt-in for $200 million. With an upgraded half-life versus its BiTE predecessors but significant competition from Amgen, Harpoon’s TriTAC platform and busted IPO stock merited a deeper dive. A full analysis follows in the paragraphs below.

Shareholder Returns

HARPUS BiotechsUS Market
7D-10.1%-1.4%-3.5%
1Y-52.7%1.8%19.4%

Return vs Industry: HARP underperformed the US Biotechs industry which returned 1.8% over the past year.

Return vs Market: HARP underperformed the US Market which returned 19.4% over the past year.

Price Volatility

Is HARP's price volatile compared to industry and market?
HARP volatility
HARP Average Weekly Movement8.4%
Biotechs Industry Average Movement8.8%
Market Average Movement6.1%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.4%

Stable Share Price: HARP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: HARP's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201592Julie Eastlandhttps://www.harpoontx.com

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors.

Harpoon Therapeutics Fundamentals Summary

How do Harpoon Therapeutics's earnings and revenue compare to its market cap?
HARP fundamental statistics
Market CapUS$186.34m
Earnings (TTM)-US$106.53m
Revenue (TTM)US$26.82m

7.7x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HARP income statement (TTM)
RevenueUS$26.82m
Cost of RevenueUS$66.53m
Gross Profit-US$39.70m
ExpensesUS$66.82m
Earnings-US$106.53m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.25
Gross Margin-148.03%
Net Profit Margin-397.17%
Debt/Equity Ratio0%

How did HARP perform over the long term?

See historical performance and comparison

Valuation

Is Harpoon Therapeutics undervalued compared to its fair value and its price relative to the market?

2.7x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HARP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HARP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HARP is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: HARP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HARP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HARP's PB Ratio (2.7x) is in line with the US Biotechs industry average.


Future Growth

How is Harpoon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

-6.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HARP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HARP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HARP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HARP's revenue (18.8% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: HARP's revenue (18.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HARP is forecast to be unprofitable in 3 years.


Past Performance

How has Harpoon Therapeutics performed over the past 5 years?

-38.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HARP is currently unprofitable.

Growing Profit Margin: HARP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HARP is unprofitable, and losses have increased over the past 5 years at a rate of 38.5% per year.

Accelerating Growth: Unable to compare HARP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HARP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: HARP has a negative Return on Equity (-138.4%), as it is currently unprofitable.


Financial Health

How is Harpoon Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: HARP's short term assets ($156.2M) exceed its short term liabilities ($55.4M).

Long Term Liabilities: HARP's short term assets ($156.2M) exceed its long term liabilities ($42.3M).


Debt to Equity History and Analysis

Debt Level: HARP is debt free.

Reducing Debt: HARP had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HARP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HARP has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 31% each year.


Dividend

What is Harpoon Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HARP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HARP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HARP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HARP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HARP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Julie Eastland (57 yo)

0.083

Tenure

Ms. Julie M. Eastland has been an Independent Non-Employee Director at Graybug Vision, Inc. since September 25, 2020. Ms. Eastland serves as Director at Dynavax Technologies Corporation since July 2020. Ms...


Leadership Team

Experienced Management: HARP's management team is considered experienced (3.2 years average tenure).


Board Members

Experienced Board: HARP's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HARP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29%.


Top Shareholders

Company Information

Harpoon Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Harpoon Therapeutics, Inc.
  • Ticker: HARP
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$186.339m
  • Shares outstanding: 32.75m
  • Website: https://www.harpoontx.com

Number of Employees


Location

  • Harpoon Therapeutics, Inc.
  • 131 Oyster Point Boulevard
  • Suite 300
  • South San Francisco
  • California
  • 94080
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 23:46
End of Day Share Price2021/12/02 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.